Drugs for allergic and eosinophilic diseases
AssigneeEnvironmental Research Institute
InventorsHirokazu Okudaira, Akio Mori
Life of this patent
Estimating the term…
Abstract
A method of inhibiting human IL-5 gene transcriptions mRNA expression and protein production by human T-cells using one or more compounds selected from those shown by formula I shown below (where R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each independently a C.sub.1 -C.sub.6 alkyl group) and a therapeutic agent for allergic and eosinophilic inflammatory diseases which contains one or more compounds selected from those shown by the formula. ##STR1##
Claims4
A method of treating an allergic disease selected from the group consisting of bronchial asthma, atopic dermatitis, pollinosis, allergic rhinitis and allergic conjunctivitis, which comprises administering to a patient having said disease a therapeutically effective amount of one or more compounds selected from those shown by formula I below in which R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each independently a C.sub.1 -C.sub.6 alkyl group ##STR4## .
A method of treating an eosinophilic inflammatory disease selected from the group consisting of eosinophilic syndrome, allergic angiitis, eosinophilic fasciitis, eosinophilic pneumonitis and PIE syndrome, comprising administering to a patient having said disease a therapeutically amount of one or more compounds selected from those shown by formula I below in which R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each independently a C.sub.1 -C.sub.6 alkyl group ##STR5## .
Dependencies are inferred from the claim text.